Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVRYT2)

• Drug Name: NABILONE Drug Info
• Synonyms: Nabilone; Nabilona; Nabilonum; Cesamet; 51022-71-0; CHEMBL947; GECBBEABIDMGGL-RTBURBONSA-N; Nabilonum [Latin]; Nabilona [Spanish]; Nabilone [USAN:INN:BAN]; DEA No. 7379; Nabilon; CPD 109514; CPD-109514; 9H-Dibenzo(b,d)pyran-9-one, 3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-, (6aR,10aR)-rel-; 9H-Dibenzo[b,d]pyran-9-one, 3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-, (6aR,10aR)-rel-

Indication

Disease Entry	ICD 11	Status	REF
Insomnia	7A00-7A0Z	Approved	[1]

• Cross-matching ID:
  PubChem CID: 5284592
  CAS Number: CAS 51022-71-0
  TTD Drug ID: DMVRYT2
  ACDINA Drug ID: D01264

Molecule-Related Drug Atlas

Drug(s) Targeting Cannabinoid receptor 2 (CB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Guanfacine extended release	DMB1CZ8	Attention deficit hyperactivity disorder	6A05.Z	Approved	[4]
GW-42004	DMY3KSU	Lipid metabolism disorder	5C52.Z	Phase 2	[5]
KHK-6188	DMF6CTI	Neuropathic pain	8E43.0	Phase 2	[6]
LY-2828360	DMO8IEZ	Pain	MG30-MG3Z	Phase 2	[6]
APD371	DM3XT5V	Crohn disease	DD70	Phase 2	[7]
S-777469	DMZGNOJ	Atopic dermatitis	EA80	Phase 2	[8]
842166X	DMOV0AP	Pain	MG30-MG3Z	Phase 2	[9]
Beta-caryophyllene	DM7583A	Pain	MG30-MG3Z	Phase 2	[10]
Vicasinabin	DMF16CU	Diabetic retinopathy	9B71.0	Phase 2	[11]
Tedalinab	DM58J7E	Pain	MG30-MG3Z	Phase 1	[12]

Drug(s) Targeting Cannabinoid receptor 1 (CB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[13]
Orlistat	DMRJSP8	Obesity	5B81	Approved	[14]
SR141716A	DMCO5JZ	Obesity	5B81	Approved	[15]
Tebipenem	DMVSX6O	Urinary tract infection	GC08	Phase 3	[16]
Conatumumab	DM2UOSN	Colorectal cancer	2B91.Z	Phase 2	[17]
GW-42004	DMY3KSU	Lipid metabolism disorder	5C52.Z	Phase 2	[5]
SR-147778	DMNAECP	Obesity	5B81	Phase 2	[18]
Nimacimab	DM21Z68	Diabetic nephropathy	GB61.Z	Phase 2	[19]
AEF0117	DMQ1GH4	Marijuana use disorder	6C41	Phase 2	[20]
V-24343	DMJSX9N	Type-2 diabetes	5A11	Phase 1	[21]

Drug(s) Affected By Cannabinoid receptor 2 (CNR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Guanfacine extended release	DMB1CZ8	Attention deficit hyperactivity disorder	6A05.Z	Approved	[22]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[23]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[24]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[25]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[26]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[27]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[28]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[29]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[30]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[31]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cannabinoid receptor 1 (CB1)	TT6OEDT	CNR1_HUMAN	Inhibitor	[2]
Cannabinoid receptor 2 (CB2)	TTMSFAW	CNR2_HUMAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cannabinoid receptor 2 (CNR2)	OTYP9P43	CNR2_HUMAN	Protein Interaction/Cellular Processes	[3]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
• [3] Cloning and pharmacological characterization of the dog cannabinoid CB?receptor. Eur J Pharmacol. 2011 Nov 1;669(1-3):24-31. doi: 10.1016/j.ejphar.2011.08.002. Epub 2011 Aug 19.
• [4] Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. Neurobiol Learn Mem. 2008 Sep;90(2):374-81.
• [5] Company report (Gwpharm)
• [6] Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands. Current Medicinal Chemistry . 10/2013; 21(2).
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs. 2009 Mar;14(1):165-79.
• [9] The agonist binding mechanism of human CB2 receptor studied by molecular dynamics simulation, free energy calculation and 3D-QSAR studies. Yao Xue Xue Bao. 2013 Sep;48(9):1436-49.
• [10] The cannabinoid CB1 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Eur Neuropsychopharmacol. 2014 Apr;24(4):608-20.
• [11] Clinical pipeline report, company report or official report of Roche
• [12] Cannabinoid CB2 receptor (CNR2). SciBX 3(46); doi:10.1038/scibx.2010.1384. Dec. 2 2010
• [13] Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411.
• [14] Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9.
• [15] Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
• [16] Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
• [17] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [18] Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77.
• [19] Clinical pipeline report, company report or official report of Bird Rock Bio.
• [20] Clinical pipeline report, company report or official report of Affimed Therapeutics.
• [21] Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs. 2009 Mar;14(1):43-65.
• [22] Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem. 2000 Jan 7;275(1):605-12. doi: 10.1074/jbc.275.1.605.
• [23] hiPSC-Based Model of Prenatal Exposure to Cannabinoids: Effect on Neuronal Differentiation. Front Mol Neurosci. 2020 Jul 6;13:119. doi: 10.3389/fnmol.2020.00119. eCollection 2020.
• [24] Comparison of protective effect of ascorbic acid on redox and endocannabinoid systems interactions in in vitro cultured human skin fibroblasts exposed to UV radiation and hydrogen peroxide. Arch Dermatol Res. 2017 May;309(4):285-303. doi: 10.1007/s00403-017-1729-0. Epub 2017 Mar 11.
• [25] Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res. 2006 Jul 1;66(13):6615-21. doi: 10.1158/0008-5472.CAN-05-4566.
• [26] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [27] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [28] Regulation of opioid and cannabinoid receptor genes in human neuroblastoma and T cells by the epigenetic modifiers trichostatin A and 5-aza-2'-deoxycytidine. Neuroimmunomodulation. 2012;19(3):180-6. doi: 10.1159/000331474. Epub 2012 Jan 18.
• [29] Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis. 2011 Apr 28;2(4):e152. doi: 10.1038/cddis.2011.36.
• [30] Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
• [31] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.